Petplan's Veterinary Awards are designed to celebrate the nation’s most outstanding vets, vet nurses, practices, practice managers and support staff who are nominated by their colleagues and clients for continually going that extra mile, keeping pets healthy and giving owners peace of mind.
The independent panel of judges said that Johanna's nomination stood out for her ability to create a balance between leading a practice which maintains incredibly high clinical standards along with a welcoming, caring ethos with patients at the heart of everything they do.
Johanna said: "I’m absolutely ecstatic! I wasn’t expecting to win at all, so this is a real surprise – I just want to say thank you to those who nominated and all my staff for supporting me every day. What a brilliant feeling!"
The other big winner on the night was 387 Veterinary Centre. Two members of staff, Nicky Smith RVN and Joanne Civil, won 'Veterinary Nurse of the Year' and 'Veterinary Practice Support Staff of the Year' respectively, and the practice also took the overall 'Veterinary Practice of the Year' award.
'Veterinary Practice Manager of the Year' went to Anne Corson of Pennard Vets in Tonbridge.
Invicta, the new, independent veterinary pharmaceutical company, has launched ChroMyco Duo, the first duo plate dermatophtye fungal test to help veterinary professionals identify the source of skin abnormalities in-house without the delay and cost of sending samples to a laboratory.
According to the Sussex-based company, ChroMyco Duo has been designed to aid practices in the accurate identification of fungal skin infections in dogs, cats, horses and all small animal species.
ChroMyco Duo is a dual plate test with dermatophyte test media (DTM) on one side and an Enhanced Sporulation Agar (ESA) on the other. Invicta says it's this dual test capability which greatly reduces the risk of false positive results. The test is performed by veterinary staff taking a pluck of fur or skin scrape from the lesion and innoculating both sides. After three to six days, if dermatophytes are present, the DTM will turn red and the ESA will turn blue-green.
Once a colour change is identified, a sample of the culture can be taken from the ESA, a media prolific in growing dermatophytes. Veterinary staff are then able to examine the fungus microscopically and identify the species of dermatophyte before advising on treatment.
Invicta has prepared a free fungal identification chart to assist practices with the identification of cultures and is providing free updates to subscribers, as images of new fungi are submitted by practices using the kit.
The ChroMyco Duo test is supplied in boxes of five units, each individually wrapped to allow a one year shelf life. It costs £5 per unit, which Invicta says makes it very cost-effective when compared to laboratory charges. It is incubated at room temperature so no specialist equipment is required.
Rob Watkins, Managing Director of Invicta, said: "The incidence of fungal infections in practice is significant and growing. Antifungal treatments already account for more than £1m sales in the UK veterinary sector. The problem is that dermatophyte presence is often misdiagnosed.
"Until recently vets have had to rely on either single test kit, or for a full diagnosis, by sending a sample to laboratory where tests cost up to £20 and can take 14 days to complete.
"With the launch of ChroMyco Duo, we're giving practices the capability to test reliably, simply and cost-effectively for the first time."
For further information on ChroMyco Duo or Invicta, please contact the company on 01403 791313 or email them at mail@invictavet.com.
In the study1, which was funded by Universities Federation for Animal Welfare (UFAW), an online questionnaire was completed by 744 snake owners worldwide but predominantly from the UK (68.8%).
The questionnaire investigated housing and husbandry practices and snake health and welfare as measured by clinical signs and behavioural indicators.
Associations between clinical signs, behavioural indicators and housing and husbandry aspects were tested for the three most common snake families: Pythonoids, Boids and Colubrids.
The study found 54.7% of snakes were kept in enclosures shorter in length or height than their body, preventing them from stretching out fully.
10.2% of snakes in the UK were kept in enclosures that do not comply with current recommended guidelines (minimum enclosure length <0.66 of snake length).
Whilst most snake owners (93.1%) reported measuring the temperature in their snakes’ enclosures, 24% of these checked less than the recommended once daily.
When looking at the most commonly owned snake species (royal pythons, corn snakes and common boa constrictors), 47.2% were kept in sub-optimal temperatures for their species.
Furthermore, 48.1% of owners reported not measuring the humidity in their snakes’ enclosure.
Owners reported that many snakes experienced at least one of the listed clinical signs, with the most common issues being skin shedding (28.2%), parasites (11.2%), rostral cuts and scrapes (7.4%) and respiratory problems (5.6%).
Snakes that were kept in enclosures <1 snake length had significantly more clinical signs compared to those snakes kept in enclosures >1 snake length.
Similarly, most snakes were reported to experience at least one of the listed negative behaviours, most commonly interacting with transparent boundaries (52.8%), wincing or withdrawal of head when gently touched (52.4%), putting the head under the substrate (52.1%), unusually high level of activity (51.1%) and attempting to escape (45.9%).
All these negative behaviours have previously been described as associated with captive stress.
Snakes that were reported as having more clinical signs tended to show more reported negative behaviours.
Dr Nicola Rooney, Senior Lecturer in Wildlife and Conservation at Bristol Veterinary School and corresponding author for the paper, said: “Our study has highlighted various concerns for snake welfare.
"The first of these relates to enclosure size, with snakes commonly being kept in vivaria preventing straight-line postures and movement.
"Snakes that were unable to stretch out fully had more clinical signs than those that were able to stretch out fully.
“Whilst we did not find a significant association between temperature or humidity and measures of health and welfare in this study, it is a concern that many snakes were housed in conditions considered sub-optimal for their species.
"We know that appropriate temperature and humidity is vital for maintaining the health of snakes and it would therefore be prudent to investigate these associations further, using methods other than owner reporting.”
Dr Huw Golledge, Animal Welfare Editor-in-Chief, said: “Until now, there has been little empirical data on the housing and husbandry practices of privately kept snakes, and how these impact on their welfare.
"As the first study of this size, this research provides valuable baseline data against which future surveys or welfare interventions can be compared.
“As this survey relies on owner-reported information, it is very likely that many of the frequencies of clinical and behavioural signs are underestimated.
"This demonstrates the need for evidence-based recommendations, and the importance of such recommendations being made accessible to owners to improve snake welfare.”
Reference
Photo: Brown and Black Snake in Close Up Photography © deedee Pexels
Matthew’s award is in recognition of his paper Approach to initial management of canine generalised epileptic seizures in primary-care veterinary practices in the United Kingdom, co-authored with Laurent Garosi, which was selected by the BSAVA Committee as being the most valuable to veterinary practice.
James’ study explored data collected as part of the Small Animal Veterinary Surveillance Network (SAVSNET) at the University of Liverpool.
In total, clinical records concerning 3,150,713 consultations (917,373 dogs) were collected and analysed from 224 UK veterinary practices.
This included the management of canine generalised epileptic seizures in 517 dogs up to 6 years of age.
The study concluded that 98% of dogs presenting for a single epileptic seizure were not started on long-term therapy, in accordance with the approach recommended by the International Veterinary Epilepsy Task Force (IVETF).
Other findings from the study included:
The paper also reported on factors potentially associated with prescription of ASDs.
It stated that dogs who presented for cluster seizures (more than one epileptic seizure in a 24-hour period) were more likely to be prescribed ASDs, or to be referred to a specialist, than dogs without cluster seizures.
Dogs that were neutered or microchipped were more likely to be started on ASDs following the initial presentation, perhaps suggesting that owners who take part in regular preventative healthcare prior to the onset of their dog’s seizures could be more willing to start therapy in the earlier stages of the disease.
In addition, more than half of dogs with cluster seizures were not prescribed any ASDs.
Given that the presence of cluster seizures is typically considered an indication to start long-term therapy by the IVETF, Matthew says this may be one aspect of seizure management that could be improved in primary care practice.
Regarding the choice of anti-seizure drugs (ASDs), imepitoin was more frequently prescribed than phenobarbital in response to cluster seizures.
But unlike phenobarbital, the paper highlighted that the market authorisation for imepitoin does not include the treatment of cluster seizures.
Therefore vets should be aware that the use of imepitoin for cluster seizures should be considered as “off-licence” - and has additional implications for obtaining informed consent.
Matthew said: “We believe this research contributes to an improved understanding of the current management strategies for canine epilepsy in general practice and how this compares to the current guidelines advised by the IVETF.
"Given the prevalence of epileptic seizures within the UK canine population, as well as the large proportion of dogs that will be managed entirely within general practice without referral to a neurologist, it is vital to ensure that the level of care being provided is optimal.
"We therefore hope that this research ultimately supports and guides general practitioners in their approach to canine epilepsy, thereby improving the quality of life of affected dogs and their owners.”
https://onlinelibrary.wiley.com/doi/epdf/10.1111/jsap.13543
Simon Wootton, Northern European Region CAG Marketing Manager at Idexx said: "It is widely accepted that 1 in 3 cats and 1 in 10 dogs will develop CKD. The adoption by IRIS of the Idexx SDMA™ renal function test is testament to its benefits, and should give vets much more time to intervene and prescribe an appropriate course of action to help improve longevity and quality of life in CKD patients."
Idexx has produced two new wall-charts for practices, intended to assist with the diagnosis, staging and treatment of CKD in dogs and cats. They are being distributed to all practices in the UK, and can also be downloaded from the Idexx website – www.idexx.eu or ordered from Idexx by ringing 00800 1234 33 99.
Stronghold Plus contains the same selamectin found in common-or-garden Stronghold, licensed for the treatment of fleas, flea allergic dermatitis, ear mites (Otodectes cynotis), roundworm (Toxocara cati), intestinal hookworms (Ancylostoma tubaeforme), biting lice (Felicola subrostratus), and for the treatment of heartworm disease caused by Dirofilaria immitis.
To that has been added sarolaner, a new acaricide and insecticide which is also effective for five weeks against Ixodes ricinus, Ixodes hexagonus, and for four weeks against Dermacentor reticulatus and Rhipicephalus sanguineus.
Clint Lewis, Executive Vice President and President International Operations, said: "The launch of Stronghold Plus enables Zoetis to offer veterinarians in the European Union a new topical choice that treats the parasites commonly presenting a threat to cats with one convenient monthly dose.
For the first time, we have combined our new, versatile parasiticide sarolaner with the active ingredient in Stronghold, selamectin, resulting in the first approval of sarolaner for use in cats. We see sarolaner as a promising platform for future product lines and lifecycle innovations and are pleased with the positive data that sarolaner and its combination continue to generate in studies.”
Domenico Otranto, Professor of Parasitology at Bari University in Italy, who has reviewed the product data of Stronghold Plus, said: "A number of laboratory and field studies show the efficacy of the single spot-on application of Stronghold Plus for at least one month. Veterinarians in Europe now have a very effective option for the treatment and control of four prominent species of ticks commonly found on cats while maintaining proven efficacy against fleas, GI worms, heartworms, ear mites and lice. Ultimately, pet owners and practitioners have a new tool for improving health and welfare of cats."
Mr Samuel had been removed from the Register in 2018 for causing unnecessary harm to numerous animals.
After being tried and convicted of several animal welfare offences alongside his former partner at Leeds Magistrates Court, Mr Samuel was sentenced to 12 weeks’ imprisonment, suspended for 12-months on the condition that he did 150 hours of unpaid work.
He was also ordered to pay a £100 fine and subjected to a disqualification order under the Animal Welfare Act for three years.
Mr Samuel’s application for restoration was based on the facts that he accepted the seriousness of his actions and that he did not challenge the DC’s 2018 decision.
The Committee also heard evidence that since his removal from the Register, Mr Samuel - who had run a first opinion veterinary practice for nine years prior to being struck off - has undertaken 340 hours of work experience with other veterinary surgeons and 20 hours of CPD.
Dr Samuel was represented by Counsel who outlined in his submissions to the Committee how Dr Samuel’s former partner had sole responsibility for the animals and that she was involved in rehoming dogs and cats and that their relationship was ‘stressful’, that this made Dr Samuel neglect his professional obligations, and that Dr Samuel was now in a different relationship and his life had been ‘transformed’ since his conviction.
The College opposed Dr Samuel being restored to the Register.
Ms Curtis, Counsel on behalf of the College, submitted to the Committee that Dr Samuel continued to represent a risk to the welfare of animals and that to allow him to be restored to the Register would undermine public confidence in the profession.
She explained that even though his sentence and Animal Welfare Act Disqualification Order had come to an end, and he was now legally able to own animals, this should not be equated with him now being fit to return to the Register.
Dr Austin Kirwan MRCVS, chairing the Committee, and speaking on its behalf, said: “Where a veterinary surgeon has shown himself to be capable of such indifference to the welfare of multiple animals, there remained, in the Committee’s view, a real risk of that indifference manifesting itself again.
"A registered veterinary surgeon is entrusted with the care of animals, often when they are at their most vulnerable, and sometimes for prolonged periods of time.
"Given the nature of the animal welfare offences committed by Dr Samuel, the Committee considered there would be a real and significant risk to animals if the high level of responsibility and trust that comes with registration were returned to him.
“For a veterinary surgeon, conduct involving neglect of animals is at the highest end of the spectrum of serious professional misconduct.
"For the reasons outlined above, the Committee considered Dr Samuel continued to represent a risk to animal welfare and thus allowing him to be restored to the Register would seriously undermine public confidence in the profession.
"For all these reasons the application to restore Dr Samuel to the Register is refused.”
The Committee’s full findings can be viewed at www.rcvs.org.uk/disciplinary
The organisations made a joint submission to the Migration Advisory Committee (MAC) as part of its review into the Shortage Occupation List which began in autumn 2018 and will report back in spring 2019.
The BVA and the RCVS had previously made calls for the profession to be added to the list in 2017 when the MAC held a call for evidence on the impact of the UK's exit from the EU on various professions. The latest submission is a development on this previous submission, focused on the need for the post-Brexit immigration system to recognise the issues affecting the veterinary workforce, which is already under-capacity, and reiterating its importance in areas such as public health, food safety, disease surveillance and control, education, research, clinical practice and animal welfare.
The submission details how the demand for veterinary services does not currently match supply and that the UK is therefore reliant on overseas registrants, particularly from the rest of the EU, who currently make up around 50% of new registrants in a given year.
The RCVS and BVA add that, in the post-Brexit immigration system, this reliance on overseas vets needs to be recognised by adding veterinary surgeons to the Shortage Occupation List, thus reducing the immigration requirements needed for overseas veterinary surgeons to live and work in the UK and streamlining the application process for employers.
Amanda Boag, RCVS President, said: "We wanted to use this submission as an opportunity to reiterate the circumstances currently facing the profession, particularly in light of the uncertainties around the UK’s exit from the EU and the impact this could have on the supply of veterinary workforce from the rest of the EU, which is crucially important in a number of areas. We need, therefore, for veterinary surgeons to be immediately added back to the list so that we can ensure that this flow of workforce continues and that animal health and welfare is protected.
"In the meantime we are continuing to work with BVA and the Department for Environment, Food and Rural Affairs (Defra) to look at how we can develop ‘home-grown’ veterinary capacity in the UK through expanding the UK veterinary education sector, increasing retention rates within the profession, and looking at how the veterinary team could be reformed to allow allied professionals, such as veterinary nurses, to take on extra tasks and free up veterinary time. However, these are all long-term projects and not quick fixes to the issues facing the profession."
As well as calling for a future immigration system to prioritise the veterinary profession, RCVS and BVA also recommend that veterinary employers be exempt from the Immigration Skills Charge to avoid additional barriers or burdens to the employment of overseas vets and recommend that there is no minimum earning cap for veterinary surgeons applying for work visas, on the basis that veterinary surgeons are "skilled professionals who may choose to work in the UK for reasons other than remuneration".
Simon Doherty, BVA President, said: "It is in MAC’s gift to reinstate vets on the Shortage Occupation List and this evidence makes a strong case for it to happen as quickly as possible.
"Vets deliver multiple benefits to animal health and welfare, public health and food safety, and they have a crucial role to play in future trade deals and keeping standards and confidence in UK exports high. The profession is also indebted to a high proportion of skilled EU vets who have chosen to make the UK their home and place of work.
"With this in mind, the future immigration system must be geared around preserving veterinary capacity rather than introducing new layers of bureaucracy or restrictions on flexible movement between roles. We have raised concerns that extending the Immigration Skills Charge to EU workers would hit some areas of the workforce disproportionately hard, particularly the abattoir industry where 95 per cent of Official Veterinarians hail from overseas.
"With uncertain times ahead and demand for some veterinary services predicted to spiral after Brexit, it has never been more pressing to take decisive action to safeguard against shortfalls in capacity and give a vital vote of confidence in the veterinary workforce."
To read the full submission, visit https://www.rcvs.org.uk/document-library/joint-rcvs-and-bva-submission-to-migration-advisory-committee/
Jurox says the reformulation will also help reduce waste associated with unpreserved ampule formulations and will help streamline portfolios with a requirement for only one buprenorphine listing.
Dr Dan Cripwell BSc (Hons) BVSc CertAVP (EM) CertAVP PgCert (VPS) MRCVS, Advanced Veterinary Practitioner and senior veterinary technical advisor at Jurox (UK) Limited, said: “I am delighted that Jurox can provide the UK veterinary market with this evolution of our multidose buprenorphine formulation. We constantly strive to provide the veterinary profession with first class clinical and technical support and our ability to perform in-house product research and development is also a great strength; this allows us to remain agile enough to make adaptations in an area where not much has changed in the past few years.
“In this instance, we were able to examine what improvements could be made to our existing drug portfolio and respond to the profession’s feedback with the redevelopment of the commonly utilised opioid analgesic, buprenorphine. Our hope is that, as well as the recent mixing claims added to the product licence, this development will encourage the best clinical use of the drug and, in turn, improve patient experience and outcome.”
For more information, contact your local Jurox account manager, phone 0800 500 3171, visit www.jurox.com/uk or email customerservice@jurox.co.uk.
Described as a first-of-its-kind, mobile-enabled digital whitepaper, the publication offers veterinary surgeons and farmers a resource on ketosis, scientific insights on the impact of the disease, and tools to help optimize dairy herd management.
According to the company, the whitepaper reveals that ketone bodies play a more significant role in metabolic diseases than was previously realized, and that beta-hydroxybutyrate is a good indicator of the presence of subclinical ketosis in dairy cattle.
Rinse Boersma, Dairy Species Manager, Animal Health, Bayer said: "Recognizing the significance of ketone bodies is a positive step towards further enhancing dairy cattle health and welfare. Veterinarians can now reliably detect the presence of subclinical ketosis in dairy herds with a simple blood test, and act quickly with the appropriate corrective measures to arrest disease progression."
Also at Congress, Bayer revealed its enhanced BCS Cowdition smartphone application, designed to support ease and accuracy of body condition scoring (BCS) of dairy cows. Bayer says the upgrade helps farmers to improve herd health management by enabling assessment of individual cows’ BCS scores based on its lactation cycle, alerts for cows that need to be attended to, and a dashboard that offers farmers an overview of their entire herd’s health.
BCS Cowdition is available in 10 languages and is free for download from the AppStore and GooglePlay.
The Committee had found Dr Elefterescu guilty of serious professional misconduct in relation to a number of charges which covered issues such as dishonesty, poor record-keeping, and failure to carry out adequate clinical examinations.
The full charges and findings of the RCVS Disciplinary Committee can be found at: www.rcvs.org.uk/disciplinary.
The Judicial Committee of the Privy Council held the appeal hearing in October last year with three Justices of the Supreme Court - Lord Kerr, Lord Carnwath and Lord Kitchin – comprising the Board.
The basis of the appeal to the Privy Council was that the Committee’s findings on the facts of the case were flawed, with his counsel saying that Dr Elefterescu 'strenuously disputes the findings by the Committee of his dishonesty and lack of professional competence and submits that there is no adequate basis for them in the evidence’.
His counsel also told the Board that the Disciplinary Committee’s sanction failed to take into account mitigating factors and that the decision to remove Dr Elefterescu from the Register was disproportionate.
In relation to the appeal against the Disciplinary Committee’s findings on the facts, the Board was not persuaded by any of the arguments put forward on behalf of Dr Elefterescu. These arguments included that the RCVS had failed to call relevant witnesses and had failed to make Dr Elefterescu aware of the significance of some evidential matters, disclosed to him.
In respect of the sanction, the Board was also unpersuaded by the arguments put forward by Dr Elefterescu’s counsel, namely that it was too harsh in its assessment of aggravating factors, did not give adequate weight to mitigating factors, and that it failed to distinguish lack of competence from misconduct.
In its judgment on the arguments put forward by Dr Elefterescu’s counsel, the Board said: "It is the opinion of the Board that these criticisms are not well founded. The Committee considered with care Dr Elefterescu’s proven and admitted conduct in relation to each of the charges and whether it fell below or far below the standard to be expected. It is to be noted in this regard that a number of the charges which were either admitted or upheld were not the subject of any challenge on this appeal.
"Overall, the Committee found that Dr Elefterescu’s clinical failures were very serious, involved failures in the basics of animal care, resulted in animal suffering and involved widespread breaches of the respondent’s [RCVS] code of professional conduct. It also expressed particular concern about its findings of dishonesty, and rightly so. That conduct was, in its view, ‘at the top end’ of disgraceful conduct in a professional respect. What is more, Dr Elefterescu had a lack of insight into his failings and a wholly unjustified confidence in his abilities which constituted an ongoing risk to animal welfare."
"These were findings which the Committee was clearly entitled to make and, in the light of them, the Board is firmly of the view that the decision of the Committee to direct the removal of Dr Elefterescu’s name from the Register cannot be impeached. The Board rejects the criticisms made of the Committee’s reasoning and the conclusions to which it came. The direction that Dr Elefterescu’s name must be removed from the Register was appropriate and proportionate."
The Judicial Committee’s full findings can be found at www.jcpc.uk/cases/docs/jcpc-2018-0060-judgment.pdf.
Pfizer Animal Health and Central Veterinary Services are collaborating in a new venture to create a unified National Benchmarking Database open to all veterinary practices.
In what it says is an unprecedented move, Pfizer will integrate 15 years' worth of data from its Performance Index practice benchmarking service (formerly known as the Fort Dodge Index) with that of the Central Veterinary Services' Management Analysis Indices (MAI). These two benchmarking services have been in co-existence for a number of years, each using different databases. Combining the data from the participating practices within each benchmarking service will create a database of almost 300 practices, representing in excess of 10% of all UK companion animal and mixed practices. This, says the company, will provide a more accurate and relevant benchmarking of UK companion animal practice performance.
The first combined reports from this new National Database will be available in May providing a comprehensive analysis for the first quarter of 2012. For Performance Index practices, this will be available via a new web portal.
Participating practices will continue to access their reports and services independently via their respective portals for PI and MAI, but will benefit from the larger database providing greater accuracy, granularity and relevance of exactly who a practice chooses to benchmark itself against. This, in turn, should provide all participating practices with an even better understanding of both their critical success factors and where there are clear opportunities for growth. Pfizer says that as ever, practice data confidentiality will be guaranteed for all subscribing practices.
Ned Flaxman, Director Business Innovation, at Pfizer Animal Health said: "We have recognised that what veterinary practices really need is to be far more specific about who they benchmark themselves against. There is little relevance to a rural mixed practice in the Lake District employing 3 full time vets (FTVE) benchmarking themselves against a large 5 FTVE companion animal practice in the centre of Manchester - you are comparing apples and pears! My vision for creating the National Database was really to increase the business benefits of practice benchmarking and enable practices to compare apples with apples. With the new system, the large urban practice in Manchester should be able to compare its performance against other urban practices in the North of England employing 5FTVE!
"To ensure practices have accurate and relevant data from which to make informed decisions to grow and thrive in these turbulent conditions, the creation of a single national benchmarking database is the only sensible solution. Although we are effectively levelling the playing field by enabling other veterinary suppliers to offer benchmarking, we believe it is the right thing to do for veterinary practices and the market as a whole. For Pfizer Animal Health, the needs of our veterinary clients are the driving force for our business decisions, veterinary support services and product development."
Martin Barrow, Managing Director of Central Veterinary Services said: "We fully agree that a single benchmarking database is the right solution for the market. The creation of this National Database, open to all practices irrespective of their supplier, will provide the participants with unique tools to give them powerful insights for their practices' future continued success.
"MAI and the Performance Index have competed with each other for years and provided a very useful added value service for their respective subscribers but when we were approached to integrate the two databases, we immediately saw the bigger picture and recognised the significant benefits this could bring to a wider audience of UK veterinary practices.
"The national database uses open standards for data collection and data is accepted from all practices irrespective of which practice management system they use. We believe it is the right thing to do for veterinary practices and brings significant benefits to the whole veterinary profession."
Practices are urged to subscribe to the PI or MAI services either independently or through one of their practice development partners. Although run from a common database each service will continue to be provided with its own unique features.
For further information on Performance Index practices should contact their Pfizer Account Manager, email Pfizer at Vetsupportplusuk@pfizer.com.
For further information on MAI, practices should contact Central Veterinary Services at mai@centralvet.com, or telephone 01359 245310
The competition is open to all UK-based undergraduate veterinary students and offers them the opportunity to work as a team to brainstorm, develop and present an innovative idea to a board of industry professionals.
Students can enter either as a single applicant or as a group (of roughly five members), with single applicants then being placed in a group with other applicants from their university. There can be more than one team representing each university.
Each student’s project can cover any aspect of veterinary health innovation. The RCVS suggests potential projects might include: innovations within veterinary education, innovations to improve sanitation and hygiene, innovations to improve veterinary-public communication and innovations to improve patient safety.
Entries must show how they have improved upon – or extended beyond – current expectations of best practice in their chosen area.
Each applicant will receive support from one of the Association of Veterinary Students’ (AVS) Vet Futures Ambassadors, as well as a mentor session with a chosen industry professional to guide them on their project.
Teams will need to submit three components for judging: a log of their progress throughout the project (which can include social media updates using the hashtag #ViVetStudentInnovation), mentor engagement and feedback, and a five-minute video ‘business pitch’.
The three finalist groups of the competition will be invited to present their pitch to a board of industry professionals at a ‘Dragon’s Den’ style event held at the RCVS ViVet 2019 Innovation Symposium on Tuesday 1 October 2019 in Manchester.
The winning and runner-up groups will then be selected and will be presented alongside the ‘mentor’s choice’ award. The Mentor’s Choice award will be selected by the team mentors. The prize will be awarded to an individual who shows excellence and enthusiasm within their work on the project.
Anthony Roberts, RCVS Director of Leadership & Innovation (pictured right), said: "This competition provides a great opportunity for veterinary students to engage with their fellow classmates across different fields of study and to work on projects that could genuinely make a difference to animal health and welfare and the way veterinary services are delivered. Teams will receive one-on-one mentoring and will be guided through the innovation process, developing skills that will be useful throughout their careers. We look forward to seeing the three finalist teams presenting at the RCVS ViVet Innovation Symposium in Manchester on 1 October."
Zoe Skinner, Vet Futures Student Representatives Team Leader, said: “This competition is a great opportunity for veterinary students to receive mentoring from experienced veterinary professionals and form contacts within our profession. It gives students a way to work together as a team and allows them to learn how to produce and develop innovative, problem-solving concepts as well as skills in delivering presentations. These are all important aspects of our career ahead, which will look brilliant on our CV’s.”
ViVet is now accepting registrations for the competition for the 2018/19 academic year. To enter, applicants must submit an online registration form. For further information, email info@vivet.org.uk.
Ceva Animal Health has introduced an improved version of Hepatosyl, its liver support supplement for horses.
Hepatosyl Plus for horses contains the same antioxidant ingredients as the original version but now also contains Silybin, the most active isomer of Silybum marianum (milk thistle)1.
According to Ceva, the addition of Silybin gives new Hepatosyl Plus a triple antioxidant approach to liver support to help neutralise free radicals within the liver. Free radicals are produced by hepatocyte mitochondria and cause oxidative damage to cell membranes, protein and DNA.
The company says Hepatosyl Plus's triple approach includes S-adenosylmethionine (SAMe), in a stable, pure and absorbable form, which is converted into the potent liver anti-oxidant glutathione and also helps to maintain bile flow; Vitamin E, which is well-known as a potent liver antioxidant, and Silybin, which works as an antioxidant by increasing cellular superoxide dismutase.
Hepatosyl Plus remains the only liver supplement to contain Vitamin K which is needed by the liver for the production of many essential clotting factors, such as factors II, VII, IX and X, making it ideally suited for pre and post anaesthetic liver support.
Ceva says an independent trial2 on horses with confirmed liver disease has demonstrated the benefits of Hepatosyl. Conducted by European Specialist in equine internal medicine Dr Tim Brazil, the trial involved seven horses of various ages and types. All animals were given Hepatosyl in addition to treatment with antimicrobials, corticosteroids, a low protein diet and vitamin B supplementation. Post SAMe supplementation tests revealed a notable reduction in raised liver enzymes, serum proteins and bile acids and the seven horses showed obvious improvements including better appetite, weight gain and demeanour.
For further product information contact Ceva Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
References1 Flatland B (2003) Botanicals, Vitamins and Minerals and the Liver2 Brazil T (2007) S-adenosylmethionine liver support supplement trial in horses
The protocol provides evidence-based best practice criteria so that hospitals and other health settings can introduce animals into the care environment.
By following it, the RCN says services will be able to ensure the safety of patients and health care staff as well as the animals and their owners, while allowing patients to reap the benefits that interaction with animals can bring.
Publication of the protocol was prompted by an RCN survey last year which found that although the majority of respondents thought animals were hugely beneficial to patients, most nurses said animals were not allowed in their workplace.
The survey found that nine out of 10 nurses believe animals can help improve the health of patients with depression and other mental health problems with 60% of respondents also acknowledging that animals can help speed patient recovery.
Amanda Cheesley, RCN Professional Lead for Long-term Conditions and End-of-Life Care, said: "Anyone who’s worked in this area can see the amazing impact animals have on the health of adults and children alike.
"However there are so many myths around the dangers of having animals in health care settings that most organisations are too concerned to try it out.
"This protocol will help to dispel these fears by supporting hospitals to include animals in the care they deliver in a safe and professional way.
"We hope that it will encourage all health services to consider how animals can help their patients and help us to remove the taboo from what is a really remarkable area of care."
The protocol has been welcomed by the British Veterinary Association. Simon Doherty, BVA Junior Vice President, said: "This new protocol highlights the importance of the bond between humans and animals. It also serves as a welcome reminder at the start of Mental Health Awareness Week of how caring for and interacting with ‘man’s best friend’ can help to relieve stress and enhance wellbeing and a sense of companionship.
"It’s positive that the working group consulted with a wide range of organisations on welfare and safety considerations in developing this protocol, as ensuring the wellbeing of both humans and animals in these settings is paramount. As a fellow member of the UK One Health Coordination Group, BVA is very pleased to see a joined-up and forward-thinking approach to this important area of work."
Photo: Therapy Dog Visiting Young Female Patient In Hospital, Monkey Business Images / Shutterstock
A campaign to reform English libel law to allow for robust criticism of scientific and medical claims without fear of legal action has been launched by journalist and author Simon Singh. It's a campaign which anyone working in the caring professions might wish to support.
The campaign comes as a consequence of legal action taken against Mr Singh by The British Chiropractic Association, which took exception (perhaps unsurprisingly) to an article he'd written in The Guardian. In the article, Mr Singh denounced claims on the BCA website that its members could use spinal manipulation to treat children with colic, ear infections, asthma, sleeping and feeding conditions, and prolongued crying as 'bogus', and criticised the BCA for 'happily promoting' these claims.
Out of curiosity, VetSurgeon rang the BCA press office this morning, and asked to be given the references for studies which it feels would support the original claims made on its site. Non have been forthcoming so far, which is a surprise. Under the circumstances, we'd have expected the BCA would have a raft of supporting evidence readily available.
But this isn't really about whether or not chiropractic works or not. The case seems to hinge upon whether Mr Singh's article implied that the BCA was being deliberately dishonest, or just delusional. He say's the latter. Unfortunately for him, Mr Justice Eady recently ruled the former, leaving Mr Singh with a bill for £100,000 worth of legal fees.
Mr Singh is to appeal. At stake is the freedom to be able to challenge scientific claims without fear of being sued. If you'd like to support this campaign, visit senseaboutscience.com and add your name to the 7000 others (including some pretty illustrious names) who have already done so.
The BVA Board oversees the performance of the Association and is responsible for corporate and financial governance and for setting the BVA’s strategic direction. It consists of nine members: the three Officers of the BVA, four Directors appointed by BVA Council and up to 2 non-veterinary Directors appointed by the Board. The Chairman is elected by the Board.
Philip, a Bristol University Veterinary School graduate, spent seven years in mixed practice in Sussex, Kent and Suffolk before embarking on a career in the veterinary pharmaceutical industry.
He became CEO of Novartis Animal Health UK Ltd in 1996 (where, incidentally, he was ultimately responsible for signing up a wet-behind-the-ears PR consultant by the name of Arlo Guthrie and giving the go-ahead for the development of vetnurse.co.uk, which in turn led to the launch of vetsurgeon.org). In 2003 he became the company's Head of Global Marketing, and in 2005, Head of Global Business Development.
Philip has also run business elective training at the Royal Veterinary College, which has provided first-hand experience of the concerns and opportunities facing new graduates within a changing profession.
Gudrun Ravetz, President of the British Veterinary Association, said: "We are delighted to announce Philip Lowndes as the new Chairman of the BVA Board. His experience and expertise in business, knowledge of the veterinary profession and involvement with BVA will be of great value as we continue to grow our membership and expand our services and support for vets, especially during the uncertainty caused by Brexit."
Philip holds previous chair experience, as Chairman of the National Office of Animal Health (NOAH) between 1997-2004, and currently sits as Chairman of both the Novartis UK Pension Trustee Board and its Investment Committee. He joined BVA’s Board in 2013 and was re-elected by BVA Council for a second term in 2016. He will be taking over from Derek Williams, who stepped down in March after seven years of tireless work as Chairman.
Gudrun said: "I also want to take this opportunity to thank Derek Williams for all the hard work he has put in over many years. In his role as Chairman Derek’s experience and expertise have been vital in helping BVA grow as an organisation."
Philip said: "I am honoured to be elected as the next Chairman of the BVA and look forward to chairing the Board as it addresses the challenges ahead. The veterinary profession needs and deserves vibrant representation and it is the Board’s role to ensure that the organisation has the ability and the resources to achieve this to the benefit of our membership."
The BVA Board also gained a new non-veterinary Board Director, Steven Anderson Dixon, from April. Mr Dixon brings with him a successful career in newspaper and magazine publishing, which will be an asset as BVA consolidates and continues to develop its portfolio of veterinary journals.
Animalcare has announced the launch of Clavubactin (amoxicillin/clavulanate) for dogs and cats, presented as 4-way split tablets in three strengths to ensure optimum dosing. The three strengths (Clavubactin 50, 250 and 500) contain 50/12.5, 250/62.5 and 500/125mg of amoxicillin and clavulanic acid respectively. Clavubactin 50mg is licensed for cats and dogs. The 250 and 500mg formulation is licensed for dogs only.
According to the company, the increased combined level of active ingredients, compared to some other clavulanate-amoxicillin products on the market, achieves recommended target weight dosing (doses always kept at 12.5mg/kg), even with animals of greater weight, minimising the risk of underdosing.
The 4-way split tablets are designed to facilitate easy and accurate dosing of all sizes of dogs and cats, from 1kg bodyweight (¼ tablet Clavubactin 50) to 50kg (1 tablet Clavubactin 500) and above.
The tablets come in aluminium blister strips of ten tablets in five packaging presentations (Clavubactin 50 and 250 are available in 100 and 250 tablet packs and Clavubactin 500 in 100 tablets).
Animalcare Product Manager Tony Liepman said "Clavubactin allows for optimum target weight dosing and together with the accuracy enabled by SmartTabs easy 4-way split, this gives peace of mind to both vet and client."
The product is supported by dosage charts and dispensing envelopes (the latter is available on request).
For further information contact Animalcare on 01904 487687, speak to your regional Animalcare representative or visit www.animalcare.co.uk/contact-us.
The guide has been written by Simon Tappin, European and RCVS Recognised Specialist in Veterinary Internal Medicine at Dick White Referrals, and is designed to offer practical advice on the appropriate use of antibiotics in general practice. It covers a range of topics including how to create an antibiotic practice policy, ways to optimise therapy and how to limit the development of antimicrobial resistance.
Simon said: "Making rational and informed antimicrobial choices is vitally important in veterinary medicine, both for the welfare of our patients and in reducing the risk of developing antimicrobial resistance.
"Highlighting this issue to vets, providing education and supporting them in making these decisions is crucial to ensure a responsible approach to antimicrobial prescribing."
Recent surveys have highlighted the need for education on this topic, with 63 per cent of vets1 stating that they would like to improve their knowledge on antimicrobials, and 90 per cent of vets2 admitting that they are concerned about antimicrobial resistance.
In addition, there's a quiz where you can test and your knowledge on antimicrobials, and enter a competition to win an iPad Pro. The quiz can be accessed at https://veraflox.typeform.com/to/KY8lxX.
The guide is available from the Bayer Vet Centre, www.vetcentre.bayer.co.uk. Alternatively, you can download it here www.bit.ly/Veraflox2016 or contact your local Bayer Territory Manager.
References
Eskimo, a reindeer at Edinburgh Zoo has received life-saving surgery just in time for Christmas, making him the first reindeer in history to receive keyhole surgery.
Vet Romain Pizzi successfully removed one of Eskimo's testes, which had been lodged in its abdomen since birth, using specialist surgical instruments donated to the zoo by one of Ark Surgical's strategic partners Surgical Innovations.
The zoo was worried that the retained testicle may have been developing into a tumour giving off abnormal hormones, and that this could become life-threatening. Thankfully, zoo surgeons found that the retained testicle, although abnormally sized, had not yet developed a tumour.
It is thought that the abnormal testicle was affecting Eskimo's production and flow of testosterone and, as a result, he was showing submissive behaviour and being bullied by the other male reindeer in the herd. He had also started to show some abnormal and delayed antler growth and development. Removing the testicle will halt any abnormal hormone production so hopefully Eskimo will return to full vigour just in time for Christmas.
Gavin O'Brien, Director at Ark Surgical said: "We were only too happy to help when Romain mentioned the challenging operation faced by Eskimo and in the season of goodwill we approached Surgical Innovations who kindly donated the instruments for this pioneering surgery."
Although laparoscopic surgery is routine in humans, the standard procedure in animals is still open abdominal surgery. Open abdominal surgery is 20 years behind human medical advances and has a number of negative factors on animals such as more post-operative pain, slower recovery and a higher risk of post-operative complications and infections.
Romain, a veterinary surgeon for the Royal Zoological Society of Scotland, based at Edinburgh Zoo, said: "Laparoscopic surgery is still very uncommon in veterinary medicine, even amongst common species such as dogs, cats and horses, so for keyhole surgery to be carried out on a reindeer shows a great advancement in veterinary surgery."
It is estimated that nearly one out of every two households in the UK are pet owners. Veterinary surgeons perform on average 600,000 open abdominal procedures annually but it is believed that less than 1% of vets currently practice laparoscopic surgery.
Romain believes that with the right instrumentation available through innovative companies such as Ark Surgical, UK vets now have more opportunity than ever to introduce laparoscopic techniques as part of their operating procedures.
Romain said: "This procedure was only really possible thanks to a cutting-edge designed retractor which we were able to use in this case. Ironically although a reindeer is a reasonably large animal, due to their unique anatomy and massive four chambered stomach that takes up most of the space in the abdomen, there is a very limited internal operating space. For this reason the operation was much more difficult than in a human, or in a dog, where there is more space to work, despite their smaller size."
"We were especially pleased with how quickly Eskimo recovered after surgery, he was standing and happily eating lichen again within 10 minutes of recovery from anaesthesia. He hardly seemed to notice he had even had surgery, although he was still slightly groggy from the anaesthesia. This would simply not have been possible with traditional open abdominal surgery, as the long wound would have been much more painful and debilitating."
The minimally invasive nature of laparoscopic surgery means there are numerous benefits for animals such as a reduction in post-operative pain, a faster recovery and reduced post-operative care. It also has a decreased risk of infection after surgery and a lower risk of any wound complications.
For veterinary surgeons laparoscopic surgery can offer better visualisation of the operated area, allowing them to be more precise and reach areas that are difficult to see in open surgery such as the liver and pelvic canal.
Romain carries out laparoscopic operations on dogs, cats and exotic pets at his own veterinary practice Inglis Veterinary Centre (Scotland) and has pioneered several new laparoscopic techniques.
He said: "Laparoscopic surgery has so many benefits for the animal, the veterinary surgeons and the zoo, so there is no reason why it should not be more common practice within veterinary surgery. I hope Eskimo's experience helps raise its profile and encourage more veterinary surgeons to look in to it as a standard surgical procedure."
Ark Surgical offers a wide range of laparoscopy instruments and peripherals to vets across the UK and to suit all budgets. The company says it is already working with many of the UK's leading vets and agencies such as the Royal Zoological Society of Scotland, as well as the UK foremost laparoscopic medical device manufacturer Surgical Innovations, to be at the forefront of veterinary laparoscopic surgery
For more information on animal laparoscopic surgery contact Ark Surgical on 01732 862882 or http://www.arksurgical.co.uk/
The new methods, published in Applied and Environmental Microbiology, use a simple swabbing technique to gather samples from the environment which FMD-susceptible animals such as cattle, sheep and pigs commonly make contact with, such as water troughs.
Researchers say the technique requires very little expertise, which makes the sampling method far more accessible, allowing a higher frequency of samples to be collected and processed during an outbreak.
FMD virus is able to survive long periods of time in the environment in the right conditions (up to three months depending on environmental factors such as pH, temperature and relative humidity), so sampling areas where infected animals may have shed virus allows scientists to detect the presence of FMD even if the animals on the farm are no longer showing clinical signs.
The researchers say that novel surveillance techniques such as this can help support a robust response to outbreaks in FMD-free countries, and can also be implemented in endemic areas, such as parts of Asia, Africa and the Middle East, as part of surveillance programs to supplement current information about the spread of FMD.
Dr Claire Colenutt, who led the research at Pirbright said: "Current surveillance methods rely on the recognition of FMD infection in susceptible animals in addition to the collection of samples from the animals which requires veterinary expertise. In keeping the approach simple, samples can be taken by individuals without prior expertise, increasing the number of potential samples, and relieving pressure on veterinary services."
Photo: FMD. Dr. D. Denev
The College was ranked seventh in the medium-sized company or organisation category (50 to 449 employees) of the Best Workplaces for Women initiative.
This year is the first that the Great Place to Work Institute has run this initiative and, in making its rankings, it looked at a number of factors including the number and proportion of women in leadership positions, pay parity between men and women, workplace policies and how they support female employees, as well as training and development and mentoring.
Amanda Boag, RCVS President, said: "I am delighted that the RCVS has been recognised for being an excellent and supportive place for women to work and pleased that the hard work of the team at Belgravia House in this area has been publicly rewarded in this way.
"One of the key themes of my Presidential year is diversity and I think it is very important that, as a regulator, we reflect the veterinary profession (which is currently 63% female for veterinary surgeons and 98% female for veterinary nurses) as far as possible. With two-thirds of the staff at the RCVS being women it demonstrates that the College is largely reflective of the profession it serves.
"However, it’s not just about the numbers and with 60% of the Senior Team at the RCVS being women, including the CEO and Registrar, it demonstrates that the College has developed a culture in which women can shatter the glass ceiling and pursue leadership roles.
"Also, with policies such as flexible working hours, encouragement of home working, shared parental leave and enhanced maternity and paternity pay, the College goes the extra mile to support working parents."
SPVS has announced that Professor Noel Fitzpatrick will appear ‘In Conversation’ with Martin Whiting, lecturer in ethics at the RVC, at the SPVS/VPMA Congress at the Celtic Manor Resort on 29/30th January 2016.
Noel is both an inspirational and a controversial figure. Few would question that his orthopaedic and neurology work has been both brilliant and life saving. Anyone close to him will tell you he is a dedicated workaholic who believes passionately in the sanctity of life.
However, some would argue that programmes like the BBC’s Bionic Vet and Channel 4’s Super Vet may raise expectations among pet owners as to what the average vet practice can do. And then there's the question of just how far practitioners should go to save / prolong an animal's life. Just because you can, does it mean you should?
These are the areas that will be explored in this hour long ‘conversation’ in a format borrowed from literary festivals. There will be an opportunity for the audience to submit their questions from the floor.
For further details and to to book, visit www.spvs-vpma-events.co.uk or call 01453 872731.
At the hearing, Dr Crawford made no admissions to the charges against him which involved allegations of: failing to provide adequate and appropriate care; failing to provide adequate clinical histories to another practice in respect of several animals; failing to treat fellow veterinary professionals and other members of staff from another practice with courtesy and respect; failing to maintain adequate clinical records; failing to have in place Professional Indemnity Insurance or equivalent arrangements; and, failing to respond to reasonable requests from the RCVS.
Dr Crawford’s representative drew the Committee’s attention to the fact that Mr Crawford was 71 years old, had no previous disciplinary findings against him and had now ceased practising, including closing his practice premises and notifying his previous clients of the closure.
His representative confirmed that Mr Crawford was fully aware that if his application was accepted, he would no longer be able to practise as a veterinary surgeon or identify as a veterinary surgeon. The Committee also noted that the RCVS had consulted with the complainants who were satisfied with the case being disposed of in this way.
Dr Martin Whiting, chairing the Committee, and speaking on its behalf, said: “Having weighed the public interest in a hearing with the registrant’s interests, the Committee determined that this is not a case in which the public interest required there to be a full hearing. Protection of the welfare of animals would also not be further served by a full hearing. The Committee decided to accede to the respondent’s application.
"The Committee considered that the adjournment on undertakings served to protect the public interest, confidence in the profession and the welfare of animals.
"The Committee carefully considered the detail of the undertakings. It decided, after due consideration that it would accept the respondent’s undertakings in the terms offered and signed."
The Committee also heard that if Dr Crawford were to apply to re-join the Register at a future point, then the adjourned case would be re-opened and a full, public Disciplinary Committee hearing would be held.
The full documentation for the case can be found at: www.rcvs.org.uk/disciplinary
The company says the new range performs as well as the leading brands and delivers consistently reliable sterilisation, but at a much lower price point than the market has seen before. The entry level 8 Litre machine retails at £1,100.
The Yeson machines range in size from an 8 litre to a 22 litre capacity and offer quiet Class B operation, 7 pre-set sterilisation programs, B&D Helix testing and a choice of printer or USB reporting.
Yeson UK MD Will Thomas said: "The autoclave market has been dominated by a few major players for many years and until now they’ve been largely unchallenged. Many people are now asking “why should I pay thousands more for a utility machine such as an autoclave? We’re just hoping that we can meet the demand."
For more information, visit www.yeson-uk.com